Equities Analysts Issue Forecasts for Agilent Technologies, Inc.’s Q3 2024 Earnings (NYSE:A)

Agilent Technologies, Inc. (NYSE:A) – Analysts at Leerink Partnrs cut their Q3 2024 EPS estimates for Agilent Technologies in a research report issued on Thursday, July 18th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn $1.25 per share for the quarter, down from their previous forecast of $1.26. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.25 per share. Leerink Partnrs also issued estimates for Agilent Technologies’ FY2024 earnings at $5.20 EPS, Q1 2025 earnings at $1.35 EPS, Q2 2025 earnings at $1.36 EPS, Q3 2025 earnings at $1.46 EPS, Q4 2025 earnings at $1.54 EPS, FY2025 earnings at $5.71 EPS and FY2026 earnings at $6.29 EPS.

A number of other analysts have also issued reports on A. Jefferies Financial Group reiterated a “hold” rating and set a $135.00 price objective (down from $152.00) on shares of Agilent Technologies in a research note on Monday, June 3rd. Evercore ISI increased their price target on shares of Agilent Technologies from $126.00 to $130.00 and gave the stock an “in-line” rating in a report on Tuesday, July 2nd. Robert W. Baird cut their price objective on shares of Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating for the company in a research report on Thursday, May 30th. UBS Group decreased their target price on shares of Agilent Technologies from $155.00 to $141.00 and set a “neutral” rating on the stock in a report on Thursday, May 30th. Finally, Wolfe Research lowered Agilent Technologies from an “outperform” rating to a “peer perform” rating in a research note on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Agilent Technologies currently has an average rating of “Moderate Buy” and a consensus price target of $138.06.

Agilent Technologies Trading Down 0.1 %

NYSE:A opened at $131.78 on Friday. Agilent Technologies has a 1 year low of $96.80 and a 1 year high of $155.35. The stock’s fifty day moving average price is $136.39 and its two-hundred day moving average price is $137.49. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.15 and a quick ratio of 1.64. The company has a market cap of $38.45 billion, a P/E ratio of 31.15, a P/E/G ratio of 4.48 and a beta of 1.05.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, May 29th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.03. The company had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.58 billion. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The company’s quarterly revenue was down 8.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.27 earnings per share.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 24th. Stockholders of record on Tuesday, July 2nd will be paid a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a dividend yield of 0.72%. The ex-dividend date of this dividend is Tuesday, July 2nd. Agilent Technologies’s dividend payout ratio (DPR) is 22.22%.

Insider Buying and Selling

In related news, SVP Dominique Grau sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the completion of the transaction, the senior vice president now owns 49,486 shares in the company, valued at $6,595,494.08. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $130.00, for a total value of $254,540.00. Following the completion of the transaction, the chief executive officer now directly owns 25,185 shares of the company’s stock, valued at $3,274,050. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $133.28, for a total value of $1,999,200.00. Following the sale, the senior vice president now directly owns 49,486 shares in the company, valued at $6,595,494.08. The disclosure for this sale can be found here. 0.33% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Western Pacific Wealth Management LP boosted its position in shares of Agilent Technologies by 18.9% during the first quarter. Western Pacific Wealth Management LP now owns 440 shares of the medical research company’s stock valued at $64,000 after purchasing an additional 70 shares in the last quarter. Ballentine Partners LLC lifted its position in Agilent Technologies by 2.5% during the first quarter. Ballentine Partners LLC now owns 2,963 shares of the medical research company’s stock valued at $431,000 after buying an additional 73 shares during the period. Haverford Trust Co boosted its holdings in shares of Agilent Technologies by 1.7% during the 1st quarter. Haverford Trust Co now owns 4,423 shares of the medical research company’s stock valued at $644,000 after buying an additional 74 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in shares of Agilent Technologies by 3.2% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 2,421 shares of the medical research company’s stock valued at $337,000 after buying an additional 75 shares in the last quarter. Finally, Carmel Capital Partners LLC grew its position in shares of Agilent Technologies by 1.2% in the 4th quarter. Carmel Capital Partners LLC now owns 6,709 shares of the medical research company’s stock worth $933,000 after buying an additional 78 shares during the period. Institutional investors own 87.42% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.